Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update

First positive net royalties1, driven by TWYMEEG® royalties and a one-time sales-based payment of JPY 500 million, fully allocated to OrbiMed Change in governance effective since August 1st, 2025, following the…

Read this Press Release: Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update

Poxel Announces the Availability of a Bond Issue for a Maximum Amount of €2.5 Million

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with…

Read this Press Release: Poxel Announces the Availability of a Bond Issue for a Maximum Amount of €2.5 Million

Poxel Announces the Opening of Reorganization Proceedings

POXEL shares to resume trading on August 11, 2025 at market opening LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company…

Read this Press Release: Poxel Announces the Opening of Reorganization Proceedings
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership